Report Adverse Event or Product Quality Complaint   

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ASN Kidney Week 2026

American Society of Nephrology (ASN) Kidney Week 2026

October 21 - 25, 2026

  1. All
  2. Saphnelo (Anifrolumab)
  3. Baxfendy (baxdrostat)
  4. Chronic Kidney Disease
  5. Farxiga (dapagliflozin)
  6. Chronic Kidney Disease & Heart Failure
  7. Lokelma (sodium zirconium cyclosilicate)
  8. Type 2 Diabetes
  9. Chronic Kidney Disease & Diabetes

HTML

Renal outcomes in patients with SLE receiving anifrolumab in the ASTER real-world study

HTML

Characteristics of patients with comorbid CKD and hypertension in the United States and Finland

HTML

InsideCKD-HTN: Understanding the impact of hypertension control across KDIGO risk categories on CKD burden

HTML

Baxdrostat effects in CKD with uncontrolled hypertension: biomarker analysis results from the phase 2 FigHTN trial

HTML

Baxdrostat/dapagliflozin versus placebo/dapagliflozin in adults with chronic kidney disease with hypertension: BaxDuo-Arctic phase 3 study design and baseline characteristics

HTML

Progression to UACR ≥ 700 mg/g in a multinational real world population with CKD: results from the PROMISE study

HTML

Using guideline-based AI to identify individuals undiagnosed or at-risk of CKD: a real-world health system analysis

HTML

Impact of guideline-directed medical therapy on eGFR slope decline: a RESET-CKD patient-level simulation

HTML

Strength of surrogate endpoint validation in chronic kidney disease: A systematic review

HTML

Disease progression and cardiorenal outcomes in patients with CKD across UACR levels in three large real-world study populations

HTML

Two-year eGFR slope and association with adverse clinical outcomes in patients with CKD: results from a multinational real-world study

HTML

Severe kidney events, chronic kidney disease (CKD) hospitalizations, and healthcare costs in patients with CKD and heart failure in the multinational CaRe study

HTML

Applying risk stratification to improve GDMT uptake and albuminuria testing in a large US nephrology practice

HTML

Association of guideline-directed medical therapy and hospitalization risk in patients with CKD

HTML

A structured provider education program increased CKD GDMT use and reduced hyperkalemia in a network of nephrology practices

HTML

UACR reduction with the oral GLP-1 receptor agonist elecoglipron in people with type 2 diabetes

HTML

Under the radar: gaps in UACR testing and high-risk albuminuria in type 1 diabetes mellitus

HTML

Renal outcomes in patients with SLE receiving anifrolumab in the ASTER real-world study

HTML

Characteristics of patients with comorbid CKD and hypertension in the United States and Finland

HTML

InsideCKD-HTN: Understanding the impact of hypertension control across KDIGO risk categories on CKD burden

HTML

Baxdrostat effects in CKD with uncontrolled hypertension: biomarker analysis results from the phase 2 FigHTN trial

HTML

Baxdrostat/dapagliflozin versus placebo/dapagliflozin in adults with chronic kidney disease with hypertension: BaxDuo-Arctic phase 3 study design and baseline characteristics

HTML

Progression to UACR ≥ 700 mg/g in a multinational real world population with CKD: results from the PROMISE study

HTML

Impact of guideline-directed medical therapy on eGFR slope decline: a RESET-CKD patient-level simulation

HTML

Strength of surrogate endpoint validation in chronic kidney disease: A systematic review

HTML

Disease progression and cardiorenal outcomes in patients with CKD across UACR levels in three large real-world study populations

HTML

Two-year eGFR slope and association with adverse clinical outcomes in patients with CKD: results from a multinational real-world study

HTML

Applying risk stratification to improve GDMT uptake and albuminuria testing in a large US nephrology practice

HTML

Association of guideline-directed medical therapy and hospitalization risk in patients with CKD

HTML

Using guideline-based AI to identify individuals undiagnosed or at-risk of CKD: a real-world health system analysis

HTML

Severe kidney events, chronic kidney disease (CKD) hospitalizations, and healthcare costs in patients with CKD and heart failure in the multinational CaRe study

HTML

A structured provider education program increased CKD GDMT use and reduced hyperkalemia in a network of nephrology practices

HTML

UACR reduction with the oral GLP-1 receptor agonist elecoglipron in people with type 2 diabetes

HTML

Under the radar: gaps in UACR testing and high-risk albuminuria in type 1 diabetes mellitus

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-115625
Last Updated 9/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States